Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Acute myeloid leukemia

Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia

Leukemia volume 33, pages 1814–1816 (2019)Cite this article

Subjects

There are unsolved questions in the field of minimal/measurable residual disease (MRD) detection by multiparameter flow cytometry (MFC) in acute myeloblastic leukemia (AML). One of them, the value of peripheral blood (PB) testing, is raised repeatedly [1]. A Pubmed search on the topic is, however, exceedingly frustrating and mostly retrieves publications based on the morphological assessment of blast cells in PB [2,3,4]. The 2007 study by Maurillo et al. [5] was the first to propose pertinent MFC data. In this work, 50 and 48 patients, respectively, were studied in MFC for matched samples of PB and bone marrow (BM) after induction and consolidation of a chemotherapy regimen. At that time, all post-induction PB and BM samples contained detectable MRD. However, the 10 patients who had no detectable PB MRD after consolidation had a significantly better outcome, highlighting the potential value of PB MRD. In 2009, very early detection of peripheral blasts in MFC during the first days of induction was also shown to be of high prognostic value [6], a result confirmed by Yu et al. in 2015 [7]. The second most pertinent work of MRD during and after chemotherapy appeared in Leukemia in 2016, from the Dutch group HOVON [8]. The relevance of MRD assessment in PB on survival was confirmed there on a larger series of 76 evaluable patients. Among them, at a threshold of 0.04% established by ROC curves, respectively, 9/55 and 2/29 patients had detectable PB MRD after induction and consolidation. Their outcome was significantly poorer than that of MRD-negative patients. A good correlation was also noted with BM MRD.

In the course of a multicenter research program on AML MRD that was supported by the French Institute of Cancer (Inca), peripheral blood (PB) sampling was recommended for an ancillary investigation, besides that of classical bone marrow (BM) assessment. Results of the latter have been published recently [9], detailing the types of patients and treatments received. This work demonstrated the robustness of a novel analysis algorithm using a patient-tailored protocol established with MFC data of the diagnosis and a fixed set of monoclonal antibodies. Being then directly applied to the same patient’s follow-up samples, this protocol allowed to detect MRD down to a level of 5 × 10−5. Patients who never had an MRD above this threshold during follow-up fared significantly better than those having at least one “positive” follow-up sample.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano L, Cloos J, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD working party. Blood. 2018;131:1275–1291.8.

    Article  CAS  Google Scholar 

  2. Arellano M, Pakkala S, Langston A, Tighiouart M, Pan L, Chen Z, et al. Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia. Cancer. 2012;118:5278–82.

    Article  Google Scholar 

  3. Bertoli S, Bories P, Béné MC, Daliphard S, Lioure B, Pigneux A, Groupe Ouest-Est d’Etude des Leucémies Aiguës et Autres Maladies du Sang (GOELAMS). et al. Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group. Haematologica. 2014;99:46–53.

    Article  Google Scholar 

  4. Short NJ, Benton CB, Chen HC, Qiu P, Gu L, Pierce S, et al. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. Am J Hematol. 2016;91:1221–6.

    Article  CAS  Google Scholar 

  5. Maurillo L, Buccisano F, Spagnoli A, Del Poeta G, Panetta P, Neri B, et al. Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. Haematologica. 2007;92:605–11.

    Article  Google Scholar 

  6. Lacombe F, Arnoulet C, Maynadié M, Lippert E, Luquet I, Pigneux A, et al. Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study. Leukemia. 2009;23:350–7.

    Article  CAS  Google Scholar 

  7. Yu C, Kong QL, Zhang YX, Weng XQ, Wu J, Sheng Y, et al. Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia. J Hematol Oncol. 2015;8:48.

    Article  Google Scholar 

  8. Zeijlemaker W, Kelder A, Oussirren-Brockhopp YJM, Scholten WJ, Snel AN, Veldhuizen D, et al. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia. Leukemia. 2016;30:708–15.

    Article  CAS  Google Scholar 

  9. Lacombe F, Campos L, Allou K, Arnoulet C, Delabarthe A, Dumezy F, et al. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia. Hematol Oncol. 2018;36:422–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology Biology, University Hospital, Nantes, France

    Cécile Guénot & Marie C. Béné

  2. Biology Laboratory, General Hospital, Le Mans, France

    Cécile Guénot

  3. Hematology Biology, University Hospital, Bordeaux, France

    Francis Lacombe & Kaoutar Allou

  4. Hematology Biology, University Hospital, Lille, France

    Florent Dumezy & Claude Preudhomme

  5. Hematology Biology, University Hospital, Limoges, France

    Jean Feuillard & Estelle Guérin

  6. Hematology Biology, University Hospital, Angers, France

    Franck Geneviève

  7. Hematology Biology, University Hospital, Dijon, France

    Julien Guy & Marc Maynadié

  8. Hematology Biology, University Hospital, Creteil, France

    Orianne Wagner Ballon

  9. Hematology Department, Hôpital Robert Debré, Paris, France

    André Baruchel

  10. Hematology Department, Hôpital Saint Louis, Paris, France

    Hervé Dombret

  11. Hematology Department, University Hospital, Angers, France

    Norbert Ifrah

Authors
  1. Cécile Guénot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francis Lacombe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kaoutar Allou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Florent Dumezy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jean Feuillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Franck Geneviève
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Estelle Guérin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Julien Guy
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Marc Maynadié
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Orianne Wagner Ballon
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Claude Preudhomme
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. André Baruchel
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hervé Dombret
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Norbert Ifrah
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Marie C. Béné
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the Groupe d’Etude Immunologique des Leucémies (GEIL)

Corresponding author

Correspondence to Marie C. Béné.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guénot, C., Lacombe, F., Allou, K. et al. Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia. Leukemia 33, 1814–1816 (2019). https://doi.org/10.1038/s41375-019-0393-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-019-0393-0

This article is cited by

Search

Advanced search

Quick links